tiprankstipranks
Advertisement
Advertisement

HK:6160 Stock Latest News

BeOne Medicines’ BRUKINSA Delivers Pivotal Phase 3 Win in Frontline Mantle Cell Lymphoma
Company AnnouncementsBeOne Medicines’ BRUKINSA Delivers Pivotal Phase 3 Win in Frontline Mantle Cell Lymphoma
6d ago
6160
BeOne Medicines’ Brukinsa shows efficacy in Phase 3 lymphoma trial
PremiumThe Fly
BeOne Medicines’ Brukinsa shows efficacy in Phase 3 lymphoma trial
6d ago
ONC
BeOne Medicines Faces RMB446 Million Tax Payment in China, Sees No Material Impact
PremiumCompany Announcements
BeOne Medicines Faces RMB446 Million Tax Payment in China, Sees No Material Impact
10d ago
6160
BeOne Medicines Grants New Equity Awards Under 2016 Incentive Plan
PremiumCompany Announcements
BeOne Medicines Grants New Equity Awards Under 2016 Incentive Plan
18d ago
6160
BeOne Medicines Files U.S. Form S-8 to Expand Equity Incentive Plans
PremiumCompany Announcements
BeOne Medicines Files U.S. Form S-8 to Expand Equity Incentive Plans
25d ago
6160
BeOne Medicines Shareholders Approve All AGM Resolutions and Refresh Board
PremiumCompany AnnouncementsBeOne Medicines Shareholders Approve All AGM Resolutions and Refresh Board
25d ago
6160
BeOne Medicines Sets Out Board and Committee Structure to Bolster Governance
Premium
Company Announcements
BeOne Medicines Sets Out Board and Committee Structure to Bolster Governance
25d ago
6160
BeOne Medicines announces presentation of Phase 3 data in CLL patients
Premium
The Fly
BeOne Medicines announces presentation of Phase 3 data in CLL patients
25d ago
ONC
BeOne Medicines Secures Multiple HKEX Rule Waivers to Support Flexible Financing and Partnerships
PremiumCompany Announcements
BeOne Medicines Secures Multiple HKEX Rule Waivers to Support Flexible Financing and Partnerships
25d ago
6160
BeOne Medicines Formalizes Compensation Committee Charter to Strengthen Governance
PremiumCompany Announcements
BeOne Medicines Formalizes Compensation Committee Charter to Strengthen Governance
25d ago
6160
BeOne Medicines Grants RSUs to 381 Employees Under Incentive Plan
PremiumCompany Announcements
BeOne Medicines Grants RSUs to 381 Employees Under Incentive Plan
1M ago
6160
BeOne Medicines price target raised to $436 from $425 at RBC Capital
PremiumThe Fly
BeOne Medicines price target raised to $436 from $425 at RBC Capital
1M ago
ONC
BeOne Medicines’ combination shows improved survival in adenocarcinoma
PremiumThe FlyBeOne Medicines’ combination shows improved survival in adenocarcinoma
1M ago
ONC
BeOne Medicines price target raised to $367 from $364 at Leerink
Premium
The Fly
BeOne Medicines price target raised to $367 from $364 at Leerink
2M ago
ONC
BeOne Wins First-in-Class U.S. FDA Nod for BCL2 Drug in Relapsed Mantle Cell Lymphoma
Premium
Company Announcements
BeOne Wins First-in-Class U.S. FDA Nod for BCL2 Drug in Relapsed Mantle Cell Lymphoma
2M ago
6160
BeOne Medicines’ Beqalzi granted accelerated approval by FDA
PremiumThe Fly
BeOne Medicines’ Beqalzi granted accelerated approval by FDA
2M ago
ONC
BeOne Medicines Grants New RSUs to 201 Employees Under Equity Incentive Plan
PremiumCompany Announcements
BeOne Medicines Grants New RSUs to 201 Employees Under Equity Incentive Plan
2M ago
6160
BeOne Medicines price target raised to $395 from $389 at Morgan Stanley
PremiumThe Fly
BeOne Medicines price target raised to $395 from $389 at Morgan Stanley
2M ago
ONC
BeOne Medicines price target raised to $409 from $405 at Barclays
PremiumThe Fly
BeOne Medicines price target raised to $409 from $405 at Barclays
2M ago
ONC
BeOne Medicines price target raised to $420 from $410 at Guggenheim
PremiumThe FlyBeOne Medicines price target raised to $420 from $410 at Guggenheim
2M ago
ONC
BeOne Medicines reports Q1 adjusted EPS $3.24 vs. $1.22 last year
Premium
The Fly
BeOne Medicines reports Q1 adjusted EPS $3.24 vs. $1.22 last year
2M ago
ONC
BeOne Medicines raises FY26 revenue view to $6.3B-$6.5B from $6.2B-$6.4B
Premium
The Fly
BeOne Medicines raises FY26 revenue view to $6.3B-$6.5B from $6.2B-$6.4B
2M ago
ONC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >